Illumina (NASDAQ:ILMN) Price Target Raised to $225.00

Illumina (NASDAQ:ILMN) had its price target boosted by stock analysts at Stifel Nicolaus from $155.00 to $225.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the life sciences company’s stock. Stifel Nicolaus’ price target points to a potential upside of 14.80% from the stock’s current price.

ILMN has been the subject of several other research reports. JPMorgan Chase & Co. raised shares of Illumina from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $125.00 to $185.00 in a research note on Wednesday, June 10th. Canaccord Genuity Group increased their target price on shares of Illumina from $140.00 to $190.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. TD Cowen reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, July 15th. Finally, Leerink Partners upped their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and an average price target of $165.18.

Illumina Stock Down 4.4%

NASDAQ:ILMN traded down $9.10 during mid-day trading on Friday, reaching $195.99. The stock had a trading volume of 475,134 shares, compared to its average volume of 1,875,352. The stock has a market cap of $29.65 billion, a P/E ratio of 36.03, a PEG ratio of 2.88 and a beta of 1.47. The business’s 50 day moving average is $175.49 and its 200 day moving average is $146.83. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina has a fifty-two week low of $88.00 and a fifty-two week high of $205.47.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The company’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts predict that Illumina will post 5.22 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the transaction, the director owned 2,830,452 shares of the company’s stock, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Scott D. Ericksen sold 500 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares of the company’s stock, valued at approximately $2,311,360. The trade was a 3.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 1,003,769 shares of company stock worth $155,710,908. Corporate insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Illumina

Several institutional investors and hedge funds have recently added to or reduced their stakes in ILMN. Empowered Funds LLC lifted its position in shares of Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock worth $737,000 after acquiring an additional 4,940 shares during the period. Sivia Capital Partners LLC bought a new stake in shares of Illumina during the second quarter valued at approximately $621,000. CW Advisors LLC acquired a new position in shares of Illumina in the second quarter valued at $275,000. Marshall Wace LLP raised its stake in shares of Illumina by 49.0% in the second quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC lifted its position in Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the period. 89.42% of the stock is currently owned by institutional investors.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Q2 results exceeded expectations: Illumina reported revenue of approximately $1.16 billion, up 9.4%–9.5% year over year and ahead of the $1.13 billion consensus estimate. Non-GAAP diluted EPS was $1.31, versus expectations of $1.23 and $1.19 a year earlier. Illumina Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its outlook: Full-year 2026 adjusted EPS guidance was increased to $5.30–$5.40, above the roughly $5.23 analyst consensus. Revenue guidance was set at about $4.6 billion, with the midpoint reportedly modestly ahead of Wall Street expectations. Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised
• Positive Sentiment: Growth drivers appear durable: Robust clinical demand and continued placements of the NovaSeq X sequencing platform supported the quarter and the guidance increase. Operating performance also improved, with GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5%. Illumina Q2 2026 Earnings Call Highlights
• Neutral Sentiment: Eli Lilly joined Illumina’s Billion Cell Atlas alliance, potentially strengthening Illumina’s position in AI-enabled drug discovery and genomic research, though the near-term financial impact was not disclosed. Eli Lilly Joins Illumina’s Billion Cell Atlas
• Negative Sentiment: Some insider-trading data shows substantially more selling than buying over the past six months. This is a potential sentiment headwind, although it does not appear to be the primary catalyst behind the current move.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.